Personal tools

MCL coexpression mm9:1903: Difference between revisions

From FANTOM5_SSTAR

Jump to: navigation, search
No edit summary
No edit summary
Line 6: Line 6:
|ontology_enrichment_disease=
|ontology_enrichment_disease=
|ontology_enrichment_uberon=UBERON:0001016!2.53e-30!75;UBERON:0001017!2.92e-30!73;UBERON:0004121!7.46e-30!95;UBERON:0000924!7.46e-30!95;UBERON:0006601!7.46e-30!95;UBERON:0010314!5.57e-24!92;UBERON:0002346!1.62e-23!64;UBERON:0003075!1.62e-23!64;UBERON:0007284!1.62e-23!64;UBERON:0010371!4.87e-22!73;UBERON:0000073!6.65e-21!54;UBERON:0001049!1.75e-19!52;UBERON:0005068!1.75e-19!52;UBERON:0006241!1.75e-19!52;UBERON:0007135!1.75e-19!52;UBERON:0000955!2.60e-17!47;UBERON:0006238!2.60e-17!47;UBERON:0002616!9.20e-17!46;UBERON:0003056!1.42e-16!49;UBERON:0002020!4.96e-15!34;UBERON:0003080!3.40e-14!40;UBERON:0002780!1.28e-13!39;UBERON:0001890!1.28e-13!39;UBERON:0006240!1.28e-13!39;UBERON:0003528!5.25e-13!29;UBERON:0002791!5.25e-13!29;UBERON:0001893!5.25e-13!29;UBERON:0000956!2.45e-09!21;UBERON:0001869!2.45e-09!21;UBERON:0000203!2.45e-09!21;UBERON:0002619!3.33e-08!17;UBERON:0000025!3.48e-08!114;UBERON:0004111!5.44e-08!122;UBERON:0002021!7.90e-08!10;UBERON:0000411!7.90e-08!10;UBERON:0001950!7.90e-08!10
|ontology_enrichment_uberon=UBERON:0001016!2.53e-30!75;UBERON:0001017!2.92e-30!73;UBERON:0004121!7.46e-30!95;UBERON:0000924!7.46e-30!95;UBERON:0006601!7.46e-30!95;UBERON:0010314!5.57e-24!92;UBERON:0002346!1.62e-23!64;UBERON:0003075!1.62e-23!64;UBERON:0007284!1.62e-23!64;UBERON:0010371!4.87e-22!73;UBERON:0000073!6.65e-21!54;UBERON:0001049!1.75e-19!52;UBERON:0005068!1.75e-19!52;UBERON:0006241!1.75e-19!52;UBERON:0007135!1.75e-19!52;UBERON:0000955!2.60e-17!47;UBERON:0006238!2.60e-17!47;UBERON:0002616!9.20e-17!46;UBERON:0003056!1.42e-16!49;UBERON:0002020!4.96e-15!34;UBERON:0003080!3.40e-14!40;UBERON:0002780!1.28e-13!39;UBERON:0001890!1.28e-13!39;UBERON:0006240!1.28e-13!39;UBERON:0003528!5.25e-13!29;UBERON:0002791!5.25e-13!29;UBERON:0001893!5.25e-13!29;UBERON:0000956!2.45e-09!21;UBERON:0001869!2.45e-09!21;UBERON:0000203!2.45e-09!21;UBERON:0002619!3.33e-08!17;UBERON:0000025!3.48e-08!114;UBERON:0004111!5.44e-08!122;UBERON:0002021!7.90e-08!10;UBERON:0000411!7.90e-08!10;UBERON:0001950!7.90e-08!10
|tfbs_overrepresentation_for_novel_motifs=0.641384,0.128156,0.612053,0.688265,0.483253,1.67884,0.803568,0.370124,1.76086,0.489964,0.755749,0.790506,0.37041,0.81685,0.502646,0,1.02248,0.473993,0.352304,0.24402,0.570433,0.197567,0.815872,0.481455,0.620553,0.846564,0.906602,0.727368,17.5639,0.290745,0.711848,1.12823,0.471365,0.854272,0.503207,0.089443,0.460474,0.786577,0.434783,0.40068,1.20358,0.717547,0.544696,1.26006,0.325217,0.675898,0.938241,0.744678,0.162985,0.539131,1.0041,0.875451,0.282443,1.2746,1.29252,0.82458,0.549352,0.776619,0.331485,0.822375,1.10737,0.885556,1.02399,0.992216,0.8366,1.03484,1.43193,1.78579,1.1025,1.63712,0.590754,0.377213,0.593145,1.32691,0.864765,0.310084,0.854076,0.926147,1.08947,0.575233,0.37865,1.04072,0.884013,0.362446,1.20828,0.11855,0.129654,0.290918,0.943446,1.94914,1.50286,1.21342,1.14153,0.490141,0.430015,0.409166,0.367176,1.14445,2.1607,1.34553,1.16494,1.12793,1.25667,1.00472,1.00361,0.717061,1.06633,0.740267,0.580757,0.57247,0.633483,1.25851,1.41174,0.7614,1.51002,0.476467,0.869142,0.692434,1.02384,0.456123,1.33244,0.970073,0.848526,0.925183,1.56496,1.09333,0.812403,1.13449,1.43038,0.493609,1.23918,0.680176,1.40022,0.839311,1.53196,4.94449,0.650785,0.719099,1.482,2.31884,1.91709,1.43673,0.861473,1.1391,0.996781,0.718046,0.941555,2.27909,0.653418,1.21803,0.79777,0.184289,1.27621,0.416214,0.838313,1.35996,0.87653,0.516549,0.63863,0.650472,1.49167,1.20739,1.09379,1.52606,0.993294,0.830321,0.459159,0.788782,0.0824127
}}
}}

Revision as of 20:36, 26 November 2012


Phase1 CAGE Peaks

 Short description
Mm9::chr10:67375223..67375240,-p4@Zfp365
Mm9::chr11:109510690..109510751,+p4@Prkar1a
Mm9::chr15:22478661..22478682,+p4@Cdh18
Mm9::chr18:13132927..13132946,+p@chr18:13132927..13132946
+


Enriched pathways on this co-expression cluster<b>Summary:</b><br>Canonical pathway gene sets were compiled from Reactome, Wikipathways and KEGG. For the major signaling pathways, the transcriptionally-regulated genes (downstream targets) were obtained from Netpath. Combined, the canonical pathways and downstream targets totaled 489 human gene sets. The corresponding M. musculus gene sets were inferred by homology using the HomoloGene database. Enrichment for each of the canonical 489 pathways and gene sets included in the co-expression cluster was assessed by the hypergeometric probability. The resulting P values were also then adjusted by the Benjamini-Hochberg method for multiple comparisons.<br><b>Analyst: </b>Emmanuel Dimont<br><br>link to source dataset<br>data


GO IDGO nameFDR corrected p-value
GO:0005952cAMP-dependent protein kinase complex0.0349580978036032
GO:0030552cAMP binding0.0349580978036032
GO:0008603cAMP-dependent protein kinase regulator activity0.0349580978036032
GO:0031594neuromuscular junction0.0349580978036032
GO:0016208AMP binding0.0349580978036032
GO:0030551cyclic nucleotide binding0.0349580978036032
GO:0001707mesoderm formation0.0349580978036032
GO:0048332mesoderm morphogenesis0.0349580978036032
GO:0001704formation of primary germ layer0.0349580978036032



Relative expression of the co-expression cluster over median <br>Analyst:





Enriched sample ontology terms on this co-expression cluster<b>Summary:</b>To summarize promoter activities (expression profile of a TSS region) across ~1000 samples, we performed enrichment analysis based on FANTOM5 Sample Ontology (FF ontology). The question here is “in which type of samples the promoter is more active”. To answer this question, we compared expressions (TPMs) in the samples associated with a sample ontology term and the rest of the samples by using the Mann-Whitney rank sum test. To summarize ontologies enriched in this co-expression cluster, we ran the same analysis on an averaged expression profile of all promoters that make up. <b>Analyst:</b> Hideya Kawaji <br><br>links to source dataset<br><br>cell_data<br>uberon_data<br><br>


Uber Anatomy
Ontology termp-valuen
nervous system2.53e-3075
central nervous system2.92e-3073
ectoderm-derived structure7.46e-3095
ectoderm7.46e-3095
presumptive ectoderm7.46e-3095
structure with developmental contribution from neural crest5.57e-2492
neurectoderm1.62e-2364
neural plate1.62e-2364
presumptive neural plate1.62e-2364
ecto-epithelium4.87e-2273
regional part of nervous system6.65e-2154
neural tube1.75e-1952
neural rod1.75e-1952
future spinal cord1.75e-1952
neural keel1.75e-1952
brain2.60e-1747
future brain2.60e-1747
regional part of brain9.20e-1746
pre-chordal neural plate1.42e-1649
gray matter4.96e-1534
anterior neural tube3.40e-1440
regional part of forebrain1.28e-1339
forebrain1.28e-1339
future forebrain1.28e-1339
brain grey matter5.25e-1329
regional part of telencephalon5.25e-1329
telencephalon5.25e-1329
cerebral cortex2.45e-0921
cerebral hemisphere2.45e-0921
pallium2.45e-0921
regional part of cerebral cortex3.33e-0817
tube3.48e-08114
anatomical conduit5.44e-08122
occipital lobe7.90e-0810
visual cortex7.90e-0810
neocortex7.90e-0810


TFBS overrepresentation<b>Summary:</b>The values shown are the p-values for overrepresentation of the motif in this coexpression cluster. So a small p-value means a strong overrepresentation. <b>Analyst:</b> Michiel de Hoon <br><br>link to source data <br> Novel motifs <br>data <br><br> Jaspar motifs <br>data


Novel motifs




JASPAR motifs


Motifs-log10(p-value)

{{{tfbs_overrepresentation_jaspar}}}